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INTRODUCTION: Long segmental diaphyseal 
bone loss often results from high energy trauma 
like blast injury, osteomyelitis or wide excision of 
malignant conditions. Treatment of these long 
segmental diaphyseal defects remains a difficult 
clinical problem. In the literature, many authors 
have reported that segmental bone defects longer 
than 2.5 cm always require bone grafting. Non-
vascularized bone graft frequently fails if the 
defect is longer than 6-7 cm. Thus, a 2.5 cm long 
bone defects is probably the critical-size defect in 
human and a 7 cm long defect is likely the critical-
size for non-vascularized bone graft. 
 Various treatment methods are adopted 
currently to address this problem, including 
vascularized bone graft, distraction osteogenesis 
and massive allograft. However, all these methods 
are associated with a lot of problems. 
 Successful guided bone regeneration has been 
achieved in skull bone and jaw bone using 
resorbable allograft. Bone regeneration in long 
segmental defect and relatively small defect in 
tumour excision has been achieved using 
resorbable polylactide scaffolds. 
 
METHODS & MATERIALS: Bioresorbable 
scaffolds (microporous membranes and 3-D 
sponges) were produced from poly(L/DL-lactide) 
80/20% with a molecular weight of 200 kD 
(PURAC Biochem; Gorinchem, The 
Netherlands). The membranes had intercon-
nected open pores with an average size of 50 to 70 
mm. The 3-D sponges had the average pore size in 
the range of 450-700 µm, and the pore-to-volume 
ratio in the scaffold 94%. 
 Ten patients with bone defect of sizes up to 6 
cm due to various causes including benign 
tumour, osteomyelitis & fractures were treated 
with resorbable polylactide scaffold impregnated 
with marrow blood which contains stromal cells. 
In cases with infection, antibiotics was also loaded 
into the scaffold and in this situation, the scaffold 
also served as a drug delivery device. The patients 
have been assessed regularly with X-rays and 
clinical symptoms. 
 
RESULTS: Serial X-ray evaluation and clinical 
evaluation revealed presence of bone regeneration. 
The limbs enjoyed satisfactory function and there 
was minimal donor site morbidity and major 
surgery can be avoided. 
 
DISCUSSION AND CONCLUSIONS: Segmen-
tal bone defects in selected clinical cases were 
treated using bioresorbable porous polymeric 
scaffolds impregnated with autogenous marrow 
blood. Such cases would be treated otherwise by 
conventional techniques. 
 Vascularized bone transfer has limited supply 
and involves a major operation. There is always a 
chance of vascular complication and there is 
donor site morbidity. There is a limitation in bone 
defect size that can be lengthened using distraction 
osteogenesis, and in addition, this procedure 
requires a prolonged placement of an external 
fixation. There is a high chance of traction injury 
to nerve and other soft tissues. 
 Massive allograft requires a prolonged period, 
in terms of decades, for complete creep 
substitution. There is also a high incidence of 
disease transmission and infection. 
 Therefore there is a constant demand for bone 
substitute which can bridge long segmental defect 
effectively with minimal morbidity and can heal in 
reasonable time frame. The affected limb can be 
rehabilitated and bear weight for functional 
restoration as early as possible. If such a substitute 
is radiolucent this would be an additional 
advantage for a radiographic assessment of bone 
healing. 
 Such a new bone substitute can be for example 
produced from bioresorbable polymers and/or 
composites consisting of bioresorbale polymers 
and calcium phosphate ceramics which would add 
and osteoconductive component to the implant. 
Impregnation of such bone substitutes with 
autogenous bone marrow or marrow blood would 
also make osteoinductive. The early promising 
results of this study show that such an approach to 
new bone substitutes is feasible. 
